10May 2023
Allogeneic hematopoietic stem cell transplantation for natural killer/T-cell lymphomas

Allogeneic hematopoietic stem cell transplantation for natural killer/T-cell lymphomas

The study retrospectively analyzed 135 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) for natural killer/T-cell lymphomas (NKTCL), a rare and aggressive type of lymphoid malignancy. Most patients had received multiple treatments, including asparaginase-based chemotherapy and prior auto-HSCT. With a median follow-up of 4.8 years, the study found that 3-year progression-free and overall survival rates were 48.6% and 55.6%, respectively. Non-relapse mortality at 1 year was 14.8%, and 1-year relapse incidence was 29.6%. The study suggests that allo-HSCT can achieve long-term survival in approximately half of patients with relapsed/refractory NKTCL.

  • #oncology

Like

Save

Share